Savara (NASDAQ:SVRA) Stock Price Up 5.6% – Here’s What Happened

Shares of Savara Inc (NASDAQ:SVRA) traded up 5.6% on Thursday . The stock traded as high as $3.20 and last traded at $3.19. 138,171 shares changed hands during trading, a decline of 89% from the average session volume of 1,266,494 shares. The stock had previously closed at $3.02.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on SVRA. Evercore ISI reaffirmed an “in-line” rating and set a $5.00 price target (down from $7.00) on shares of Savara in a report on Wednesday, November 13th. HC Wainwright lowered their target price on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a research note on Thursday. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.17.

Savara Trading Up 6.0 %

The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. The stock has a market cap of $549.18 million, a PE ratio of -7.44 and a beta of 0.92. The firm has a 50-day simple moving average of $3.49 and a 200-day simple moving average of $4.00.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, meeting analysts’ consensus estimates of ($0.11). Equities analysts forecast that Savara Inc will post -0.45 earnings per share for the current year.

Insider Transactions at Savara

In other news, Director Joseph S. Mccracken bought 20,000 shares of the stock in a transaction dated Tuesday, November 19th. The stock was bought at an average price of $2.95 per share, for a total transaction of $59,000.00. Following the purchase, the director now directly owns 210,837 shares in the company, valued at $621,969.15. This trade represents a 10.48 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Matthew Pauls sold 54,702 shares of the company’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $3.31, for a total transaction of $181,063.62. Following the completion of the sale, the chief executive officer now directly owns 1,536,379 shares in the company, valued at $5,085,414.49. This represents a 3.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.13% of the company’s stock.

Institutional Trading of Savara

Institutional investors have recently made changes to their positions in the stock. Vestal Point Capital LP raised its position in shares of Savara by 24.7% during the third quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock valued at $34,302,000 after buying an additional 1,600,000 shares during the last quarter. Frazier Life Sciences Management L.P. increased its holdings in Savara by 103.9% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock valued at $32,874,000 after acquiring an additional 4,157,385 shares during the last quarter. Nantahala Capital Management LLC increased its holdings in Savara by 198.2% in the 2nd quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company’s stock valued at $20,879,000 after acquiring an additional 3,443,541 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Savara by 54.0% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 690,609 shares of the company’s stock worth $2,928,000 after purchasing an additional 242,249 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Savara by 238.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 911,617 shares of the company’s stock valued at $3,865,000 after purchasing an additional 642,259 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.